Bone News and Research

RSS

AlloSource receives US patent for cleaning and disinfecting system

AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, has been awarded its first patent for a propriety tissue cleaning and disinfecting process called RICA.

16 Mar 2010

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Treating non-osteoporotic compression fractures in patients with multiple myeloma, a blood cancer, shows that the use of vertebroplasty-a minimally invasive treatment performed by interventional radiologists using imaging guidance that stabilizes collapsed vertebrae with the injection of medical-grade bone cement into the spine-results in a reduction of pain, medication usage and disability, according to researchers in the largest study of its kind at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Vertebroplasty: Patient selection vital

Patient selection is key for vertebroplasty—a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy—to be effective and successful, according to a study of more than 1,500 persons who were followed over seven years. Additionally, collaboration between an interventional radiologist and other medical experts in treating a patient is imperative, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

GTx reacquires full rights to Ostarine

GTx, Inc. today provided a company update and reported financial results for the fourth quarter and full year 2009.

15 Mar 2010

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.

15 Mar 2010

Military surgeons update management of high-energy knee injuries

The ongoing wars in Iraq and Afghanistan have resulted in uniquely destructive patterns of combat injuries, including limb-threatening injuries to the knee. In the March special issue of Techniques in Knee Surgery military surgeons serving in Operation Iraqi Freedom and Operation Enduring Freedom share their experience with managing these high-energy injuries of the knee. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

15 Mar 2010

WWF, TRAFFIC welcome WFCMS statement on banning use of tiger bones for medicinal benefits

WWF and TRAFFIC welcome a World Federation of Chinese Medicine Societies statement urging its members not to use tiger bone or any other parts from endangered wildlife.

15 Mar 2010

ACL knee reconstruction patients well and active after 15 years

Eighty-four percent of males who had ACL knee (anterior cruciate ligament) reconstruction with a patellar tendon (the tendon that attaches the knee to the front of the tibia or shin bone) graft continue at a high level of activity 15 years later, according to a study presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day in New Orleans, Louisiana (March 13). Additionally, these patients have not developed severe osteoarthritis and their knees remain stable.

15 Mar 2010

Supplementing vitamin D in people with low levels may have different effects based on patient race

Vitamin D is quickly becoming the "go-to" remedy for treating a wide range of illnesses, from osteoporosis to atherosclerosis. However, new evidence from a Wake Forest University School of Medicine study suggests that supplementing vitamin D in those with low levels may have different effects based on patient race and, in black individuals, the supplement could actually do harm.

15 Mar 2010

New laboratory technique may help prioritize cancer drugs for clinical trials

Improving on traditional screening tests for potential anti-cancer drugs, scientists at Dana-Farber Cancer Institute have developed a laboratory technique that more closely simulates the real-world conditions in which tumor cells mingle with the body's normal cells.

15 Mar 2010

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

Zimmer Holdings showcases Continuum Acetabular Cup System at AAOS 2010

Zimmer Holdings, Inc., a leader in musculoskeletal care, today showcased its recently introduced Continuum Acetabular Cup System at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting. The Continuum Cup combines the best of Zimmer's proven hip technologies – Trabecular Metal™ Technology, Metasul® Metal-on-Metal technology, BIOLOX® delta and Longevity® Highly Crosslinked Polyethylene – with new innovations in what is now the company's most versatile acetabular cup system.

12 Mar 2010

MiddleBrook Pharmaceuticals full-year 2009 revenues rise 67.7%

MiddleBrook Pharmaceuticals, Inc. today announced its 2009 fourth quarter and full-year results, that it is further restructuring to reduce expenses, and that it is evaluating strategic alternatives to maximize shareholder value.

12 Mar 2010

ARS study underlines the importance of vitamin D and its ability to help body utilize calcium

Increasing calcium intake is a common--yet not always successful--strategy for reducing bone fractures. But a study supported in part by the Agricultural Research Service (ARS) underscores the importance of vitamin D and its ability to help the body utilize calcium. The study also may explain why increasing calcium alone isn't always successful in dealing with this problem.

12 Mar 2010

$Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur$

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons.

12 Mar 2010

Genetix Pharmaceuticals announces completion of $35M Series B financing

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.

12 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

$Stryker's Orthopaedics Division releases three new plating systems for bone fracture repair$

Stryker's Orthopaedics Division releases three new plating systems for bone fracture repair

Stryker Corporation's Orthopaedics Division today announced the release of three new plating systems: the VariAx Elbow Locking Plate System, the VariAx Fibula Locking Plate System and the AxSOS Extremity Plating System, which are all designed to expand the range of treatment options for bone fracture repair.

From Stryker 12 Mar 2010

New micromanipulator for precise operations involving cochlear and middle ear implants

A team of engineers from the CEIT-IK4 technological centre and doctors from the University Hospital of Navarra have designed a new tool for operating on the inner ear with maximum precision, reducing the possibility of damage to the auditory function during the surgery. This is the first micromanipulator specifically for operations involving cochlear and middle ear implants, of which about a hundred are carried out in this hospital annually. Taking part in developing the new tool were four engineers from CEIT and five ear, nose and throat specialists from the University Hospital of Navarra.

12 Mar 2010

Bone News and Research

AlloSource receives US patent for cleaning and disinfecting system

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Vertebroplasty: Patient selection vital

GTx reacquires full rights to Ostarine

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Military surgeons update management of high-energy knee injuries

WWF, TRAFFIC welcome WFCMS statement on banning use of tiger bones for medicinal benefits

ACL knee reconstruction patients well and active after 15 years

Supplementing vitamin D in people with low levels may have different effects based on patient race

New laboratory technique may help prioritize cancer drugs for clinical trials

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Zimmer Holdings showcases Continuum Acetabular Cup System at AAOS 2010

MiddleBrook Pharmaceuticals full-year 2009 revenues rise 67.7%

ARS study underlines the importance of vitamin D and its ability to help body utilize calcium

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Genetix Pharmaceuticals announces completion of $35M Series B financing

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

Development of promising new cancer therapies: OICR announces $1M investment

Stryker's Orthopaedics Division releases three new plating systems for bone fracture repair

New micromanipulator for precise operations involving cochlear and middle ear implants

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News